The new products offer 3,000 mg to 6,000 mg and will come in 30 and 60 ml bottles, providing significant cost savings for the fast-growing Brazilian market.
SAN DIEGO, CA – January 24, 2023 – Medical marijuana, Inc. (OTC: MJNA) (“the Company”), the first publicly traded cannabis company in the United States that launched the first cannabis-derived products, brands, and supply chain, today announced that its subsidiary HempMeds® Brasil Launched two new full spectrum products in Brazil. The two products represent the most competitively priced products available in the region, creating greater market opportunities for the subsidiary.
HempMeds® Brasil and Medical Marijuana, Inc. First two companies to receive historic first-of-its-kind permits to import hemp-based cannabidiol (CBD) oil after a Brazilian family successfully sued Brazil’s FDA equivalent, the Brazilian Health Monitoring Industry (ANVISA), for the right to access CBD oil for a child with epilepsy CDKL5. Since then, HempMeds Brasil has seen a steady growth in reaching new patients through its relationships with various medical associations as well as its direct business with consumers. CBD products sold in Brazil require a doctor’s prescription, and once obtained, HempMeds Brazil helps patients obtain the prescribed product.. The company has long been in the process of obtaining the necessary approvals to distribute its products through pharmacies as well.
“Brazil has become one of the largest and most well-established markets for CBD in the world through a structured system that includes physicians, pharmacies, and a state-sponsored insurance program – and we at HempMeds have been integral in building that from the start,” said HempMeds ® Brazil CEO Matheus Batelli. “We have truly become a leader in the global cannabis CBD space since these recent events, and we are proud to share that we have grown 50% year-on-year since establishing operations in 2014, having imported over 140,000 safe, high-quality cannabis products safely into Brazil. We are We believe in free access to the CBD for all Brazilian citizens.”
HempMeds® Brasil’s new full spectrum concentrates will supply from 3,000 mg to 6,000 mg and will come in packages of 30 and 60 ml. This opportunity and pricing model delivers significant cost savings to the fast-growing Brazilian market.
Added Batelli, “With the positive new developments, CBD products are now sold on pharmacy shelves under a special drug designation that shows that hemp-based CBD is a health and wellness product and not a pharmaceutical drug. The future in Brazil is bright, and our entire team could not be more thrilled to help others.” An important part of this work.”
“Growing and driving the Brazilian cannabis market is a key part of our company story, and these two complete new products represent a very solid growth plan that we’re executing every day,” said Blake, CEO of Medical Marijuana. Schroeder. “There is a lot of exciting news to come about cannabis in 2023, but the Brazilian market has always distinguished itself in that it started from helping a family in need. We remain committed to being a leader in the cannabis industry, and driving positive global change as we do so,”
To learn more about HempMeds® Brasil, please visit www.hempmeds.com.br.
About HempMeds® Brasil
HempMeds® Brasil was the first company to obtain approval from the National Health Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from cannabis, a plant of the genus Cannabis. Currently, it is authorized to supply its products which help in controlling diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, by prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications. www.hempmeds.com.br.
About Medical Marijuana, Inc.
We are Firsts®. Medical marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabis space: a global group of hemp-based nutritional brands led by Kanawee® And HempMeds®; leader in sourcing high quality, legal, non-psychoactive cannabis products derived from industrial hemp; and the cannabis-based clinical research and plant-based drug development segment led by pharmaceutical investment firms and their partners incl AXIM® Biotechnologies, Inc. And Neurobatics. Medical Marijuana, Inc. As the best CBD product by CNBC. Medical Marijuana, Inc. Also the first company to obtain historical import authorizations for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in the development of international markets. The company’s main product Real scientific hemp oil It has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc. is headquartered in In San Diego, California, additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. Watch the Medical Marijuana, Inc. video. , click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, and is subject to the safe harbor laws established by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and are subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ. materially from the data presented here.
Disclosure to the Food and Drug Administration (FDA)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that violate the US Controlled Substances Act.